We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.8%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$5.06B
AUM Growth
+$476M
Cap. Flow
+$367M
Cap. Flow %
7.25%
Top 10 Hldgs %
27.38%
Holding
165
New
14
Increased
67
Reduced
10
Closed
9

Top Buys

Rank Stock Value
1
AGL icon
Agilon Health
AGL
+$245M
2
LENZ
LENZ Therapeutics
LENZ
+$53.5M
3
NEUE
NeueHealth
NEUE
+$40.7M
4
VERV
Verve Therapeutics
VERV
+$40M
5
LFST icon
Lifestance Health
LFST
+$39.6M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$100M
2
AZN icon
AstraZeneca
AZN
+$32.3M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$27.2M
4
INSP icon
Inspire Medical Systems
INSP
+$20.7M
5
UNH icon
UnitedHealth
UNH
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 94.21%
2 Consumer Staples 1.63%
3 Industrials 0.71%
4 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHAS
126
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$6.86M 0.14%
1,843,764
+289,790
+19% +$965K
TARA icon
127
Protara Therapeutics
TARA
$231M
$6.75M 0.13%
693,542
+3,600
+0.5% +$40.8K
DSGN icon
128
Design Therapeutics
DSGN
$877M
$6.6M 0.13%
332,050
+4,800
+1% +$121K
ADAP
129
DELISTED
Adaptimmune Therapeutics
ADAP
$6.58M 0.13%
1,545,000
– –
TRIL
130
DELISTED
Trillium Therapeutics Inc.
TRIL
$6.1M 0.12%
628,500
+7,700
+1% +$72.5K
FATE icon
131
Fate Therapeutics
FATE
$323M
$6.08M 0.12%
70,000
– –
ATAI icon
132
AtaiBeckley Inc
ATAI
$2.68B
$5.83M 0.12%
+315,028
New +$5.82M
GRTX
133
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$5.59M 0.11%
568,252
– –
FOCL
134
EDAP TMS S.A.
FOCL
$231M
$5.39M 0.11%
+760,900
New +$5.52M
TLPH icon
135
Talphera
TLPH
$73.2M
$5.23M 0.1%
189,438
+165
+0.1% +$4.42K
BCEL
136
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$3.92M 0.08%
459,830
+5,900
+1% +$60.4K
TPST icon
137
Tempest Therapeutics
TPST
$16.1M
$3.47M 0.07%
+23,859
New +$5.36M
BLSA
138
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$3.25M 0.06%
309,000
– –
PSTX
139
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$2.9M 0.06%
289,754
– –
NUVB icon
140
Nuvation Bio
NUVB
$2.29B
$2.25M 0.04%
241,485
-160,603
-40% -$1.83M
EUCRU
141
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$2.1M 0.04%
206,000
– –
PRDS
142
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$2.09M 0.04%
209,332
– –
TMPMU
143
DELISTED
Turmeric Acquisition Corp. Unit
TMPMU
$2.07M 0.04%
206,000
– –
JYAC
144
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.05M 0.04%
206,200
– –
PHICU
145
DELISTED
Population Health Investment Co., Inc. Unit
PHICU
$2.04M 0.04%
201,044
– –
MLTX icon
146
MoonLake Immunotherapeutics
MLTX
$1.47B
$1.6M 0.03%
154,500
– –
NUVB.WS
147
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$348K 0.01%
134,028
– –
WHWK
148
Whitehawk Therapeutics
WHWK
$263M
$225K ﹤0.01%
+8,892
New +$203K
AZN icon
149
AstraZeneca
AZN
$252B
– –
-325,000
Closed -$32.3M
BAX icon
150
Baxter International
BAX
$14.4B
– –
-140,000
Closed -$11.8M
3 4 5
6
7

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Rock Springs Capital Management held 165 positions worth $5.06B, up 10% from $4.58B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management deployed $367M of net new capital in Q2 2021, opening 14 new positions and adding to 67 existing holdings. Its largest new stake was Agilon Health: 279,961 shares worth $284M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Consumer Staples and Industrials.

On the sell side, the largest reduction was Atea Pharmaceuticals, an estimated $27.2M trimmed.

  • Rock Springs Capital Management's largest Q2 2021 buy was Agilon Health: 279,961 shares worth $284M.
  • Rock Springs Capital Management added most to Eargo, Inc. Common Stock in Q2 2021, an estimated $25.1M increase.
  • Rock Springs Capital Management's biggest Q2 2021 reduction was Atea Pharmaceuticals, cutting an estimated $27.2M.
  • Rock Springs Capital Management fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $100M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $5.06B portfolio in Q2 2021.
  • Rock Springs Capital Management opened 14 new positions and closed 9 in Q2 2021.
  • Rock Springs Capital Management's portfolio value rose 10% quarter-over-quarter to $5.06B.

Based on Rock Springs Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.